Nanospectra Biosciences, Inc.
Ultra-focal, Patient focused - Leveraging nanoshells in the first true focal therapy
Ultra-focal, Patient focused - Leveraging nanoshells in the first true focal therapy
Nanospectra Biosciences, Inc. is a pioneering medical device company focused on the patient-centric use of nanomedicine for selective thermal ablation. Their lead product, AuroLase, is designed for the ablation of prostate cancer tissue, offering ultra-focal therapy to maximize treatment efficacy while minimizing side effects associated with traditional treatments. The company, founded in 2002, is strategically positioning itself through clinical advancements, exclusive partnering agreements, and ongoing research and development in the Biotechnology, Health Care, and Pharmaceutical industries. Nanospectra's technology development has been supported by grants, private equity investments, and corporate partnerships. Their most recent milestone is a significant $6.07MVenture Round investment, marking a crucial step for the company's vision. With its headquarters in the United States, Nanospectra Biosciences is dedicated to revolutionizing cancer treatment through innovative nanoshell technology.
| Funding Stage | Amount | No. Investors | Investors | Date |
|---|---|---|---|---|
| Venture Round | $6.07M | - | 15 Mar 2023 | |
| Series B | $3.00M | 1 | Sirtex Medical | 08 Sep 2020 |
| Venture Round | $2.03M | - | 09 Feb 2017 | |
| Venture Round | $946.00K | - | 12 Dec 2015 | |
| Venture Round | $800.00K | - | 08 Sep 2014 |
No recent news or press coverage available for Nanospectra Biosciences, Inc..
We care about your data, and we'd love to use cookies make your experience better.
